Hawaii, USA-based Bioponic Phytoceuticals says that Curecumin, its bioresonant phytotherapeutic formulation of curcumin, may be an important treatment for prostate cancer.
According to the firm, curcumin, which is a turmeric root extract, has been shown to possess activity in the treatment and prevention of cancer, multiple sclerosis and Alzheimer's disease. While the molecular mechanism for its anticancer effect is largely unknown, it is thought to inhibit the synthesis of MDM2, an oncoprotein known to bind p53 and modulate p21 expression, said Bioponic.
In the March 1 issue of Cancer Research, researchers from the University of Alabama reported results for curcumin in a preclinical prostate cancer model. They found that the agent decreased mRNA and protein expression of the MDM2 oncoprotein and enhanced the expression of tumor modulator p21, pointing to a potential role for Curcumin in prostate cancer, a condition which affects an estimated one in six Americans.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze